A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.

Haugh, Margaret; Gresset-Bourgeois, Viviane; Macabeo, Bérengère; Woods, Anne; Samson, Sandrine I

Haugh, Margaret; Gresset-Bourgeois, Viviane; Macabeo, Bérengère; Woods, Anne; Samson, Sandrine I.

Afiliação

Haugh M; a MediCom Consult , Villeurbanne , France.
Gresset-Bourgeois V; b Department of Medical Affairs, Value and Access and Pharmacovigilance , Sanofi Pasteur , Lyon cedex 07 , France.
Macabeo B; b Department of Medical Affairs, Value and Access and Pharmacovigilance , Sanofi Pasteur , Lyon cedex 07 , France.
Woods A; b Department of Medical Affairs, Value and Access and Pharmacovigilance , Sanofi Pasteur , Lyon cedex 07 , France.
Samson SI; b Department of Medical Affairs, Value and Access and Pharmacovigilance , Sanofi Pasteur , Lyon cedex 07 , France.

Expert Rev Vaccines ; 16(6): 545-564, 2017 06.

Article em En | MEDLINE | ID: mdl-28460594

Assuntos

Vacinas contra Influenza/efeitos adversos; Vacinas contra Influenza/imunologia; Influenza Humana/prevenção & controle; Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos; Humanos; Resultado do Tratamento; Vacinas de Produtos Inativados/efeitos adversos; Vacinas de Produtos Inativados/imunologia

Palavras-chave

Seasonal influenza; influenza vaccine; trivalent split-virion inactivated vaccine; vaccine effectiveness; vaccine efficacy; vaccine immunogenicity; vaccine reactogenicity; vaccine safety

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google